东亚药业
(605177)
| 流通市值：31.87亿 | | | 总市值：31.87亿 |
| 流通股本：1.14亿 | | | 总股本：1.14亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 352,582,674.1 | 1,356,448,097.16 | 1,004,493,194.33 | 674,178,169.83 |
| 营业收入 | 352,582,674.1 | 1,356,448,097.16 | 1,004,493,194.33 | 674,178,169.83 |
| 二、营业总成本 | 326,656,986.63 | 1,229,896,097.02 | 906,324,880.93 | 610,991,722.4 |
| 营业成本 | 263,022,490.14 | 995,092,507.87 | 742,028,476.25 | 510,496,783.93 |
| 税金及附加 | 2,195,494.95 | 9,990,045.09 | 8,179,869.21 | 4,755,333.4 |
| 销售费用 | 2,667,587.64 | 13,826,393.48 | 11,958,052.25 | 7,915,567.87 |
| 管理费用 | 40,657,303.31 | 137,159,491.03 | 96,396,943.3 | 61,141,274.06 |
| 研发费用 | 19,280,144.23 | 81,737,634.3 | 53,599,947.01 | 30,662,041.97 |
| 财务费用 | -1,166,033.64 | -7,909,974.75 | -5,838,407.09 | -3,979,278.83 |
| 其中:利息费用 | 711,807.01 | 3,598,551.43 | 2,624,896 | 1,584,174.4 |
| 其中:利息收入 | 1,532,162.9 | 11,230,923.1 | 8,110,610.82 | 5,485,064.71 |
| 加:投资收益 | 1,898,318.24 | 7,028,807.9 | 5,370,511.44 | 3,520,841.24 |
| 资产处置收益 | -3,257.83 | -2,250,572.3 | -2,235,007.09 | -2,235,007.09 |
| 资产减值损失(新) | -465,420.35 | -8,471,811.1 | -5,957,653.06 | -802,521.02 |
| 信用减值损失(新) | -4,848,150.68 | -3,015,585.09 | -5,657,127.35 | -4,741,403.01 |
| 其他收益 | 6,082,668.3 | 17,127,674.07 | 9,533,187.5 | 6,021,644.11 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 28,589,845.15 | 136,970,513.62 | 99,222,224.84 | 64,950,001.66 |
| 加:营业外收入 | - | 3,202,623.94 | 79,443 | 66,088 |
| 减:营业外支出 | 623,454.5 | 5,482,236.65 | 4,264,473.63 | 2,963,276.07 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 27,966,390.65 | 134,690,900.91 | 95,037,194.21 | 62,052,813.59 |
| 减:所得税费用 | 3,927,192.61 | 13,441,501.41 | 9,474,764.38 | 7,441,797.9 |
| 六、净利润 | 24,039,198.04 | 121,249,399.5 | 85,562,429.83 | 54,611,015.69 |
| 持续经营净利润 | 24,039,198.04 | 121,249,399.5 | 85,562,429.83 | 54,611,015.69 |
| 归属于母公司股东的净利润 | 24,039,198.04 | 121,249,399.5 | 85,562,429.83 | 54,611,015.69 |
| (一)基本每股收益 | 0.21 | 1.07 | 0.75 | 0.48 |
| (二)稀释每股收益 | 0.16 | 0.97 | 0.71 | 0.48 |
| 八、其他综合收益 | - | 418,781.05 | - | - |
| 归属于母公司股东的其他综合收益 | - | 418,781.05 | - | - |
| 九、综合收益总额 | 24,039,198.04 | 121,668,180.55 | 85,562,429.83 | 54,611,015.69 |
| 归属于母公司股东的综合收益总额 | 24,039,198.04 | 121,668,180.55 | 85,562,429.83 | 54,611,015.69 |
| 公告日期 | 2024-04-30 | 2024-04-24 | 2023-10-31 | 2023-08-11 |
| 审计意见(境内) | | 标准无保留意见 | | |